Pseudomonas Aeruginosa Treatment Market Outlook – 2027
Pseudomonas aeruginosa is an encapsulated, gram-negative, rod-shaped bacteria which cause disease in people. It is a versatile "blue-green pus bacteria" that infects people, who are weakened immune system and it is related with serious infections such as hospital-acquired infections including ventilator-associated pneumonia and sepsis syndromes. Various types of pseudomonas aeruginosa infections are occurred in human body such as pneumonia, cystic fibrosis, urinary tract infection, and bloodstream infection. For the treatment of pseudomonas aeruginosa infections various antibiotic available in the market such as aminoglycoside, cephalosporin, carbapenem, and monobactam. This antibiotic are most commonly used across the globe. As pseudomonas aeruginosa infection is most common infections in hospital which rises the demand for diagnosed with pseudomonas aeruginosa infection. Due to this major market player have many drugs are in pipeline for the treatment of this infection. This factor propel the pseudomonas aeruginosa infection pseudomonas aeruginosa treatment market growth.
COVID-19 Scenario Analysis:
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
The ongoing outbreak of COVID-19 pandemic impacted the pharmaceutical industry positively. It affect pseudomonas aeruginosa treatment market. Recently, “oral ciprofloxacin” drug product are used to treat p. auregeniosa infected patient with COVID-19 Pneumonia in Patients with COVID-19. The expanded therapy for P aeruginosa and methicillin-resistant S aureus reduce antibiotic use in patients. “America Thoracic Society and Infection Disease” provide guideline for the treatment of adults with community acquired pneumonia and COVID-19. This factors propel the growth of market.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:
Globally, Europe is hold the largest market share and dominate overall pseudomonas aeruginosa infection treatment market owing the increasing incidence of pseudomonas aeruginosa infections including urinary tract infection, pneumonia, and other hospital-acquired infection, presence of major market player, and large number of the launch of new products for the treatment of pseudomonas aeruginosa infection.
North America considered as a second largest share for pseudomonas aeruginosa infection treatment market due the presence of a large number of target population infected by pseudomonas aeruginosa bacteria, growing awareness amongst the people, and presence of well-developed hospital facilities. Whereas, Asia Pacific anticipated to expand pseudomonas aeruginosa infection treatment market growth due to the presence of a large patient pool with nosocomial infections related with P. aeruginosa, rising in antibacterial resistance.
According to “WHO” 2019 report, approximately 51,000 cases of pseudomonas aeruginosa infection are found in U.S. each year. In 2019, “Agency for Healthcare Research and Quality”, state that around 650,000 patients with pseudomonas aeruginosa infections found annually across the globe. In 2017, American Association for the Advancement of Science, reported that 7.9% of patients with a hospital-acquired infection in canadian hospitals. “Centers for Disease Control and Prevention”, state that, in the U.S more than 2 million infections and 23,000 deaths are associated with bacterial drug resistance every year. In 2018 scientist “Nicole Fosse” research that during the phase I clinical trial period, patients with P. aeruginosa bloodstream infections (BSI) were identified. Combination therapy was administered in 42.8% and remaining 57.2% were treated with monotherapy and research concluded that mortality was lower in patients receiving definite combination therapy, as compared to monotherapy and combination therapy showed good results.
The major factors such as growing patient population infected with pseudomonas aeruginosa infection, increasing demand for treatment associated with pseudomonas aeruginosa infection, increasing incidence of co-morbidities such as pneumonia, cystic fibrosis, urinary tract infection & bloodstream infection, increasing development of product for pseudomonas aeruginosa infection treatment options, increasing antibacterial resistance and growing R&D activities are drive the growth of pseudomonas aeruginosa infection market. However, the factors that hinder the growth of market including insignificant return on investment, inappropriate prescription, decreasing in development of pseudomonas aeruginosa infection treatment, and high cost of treatment etc. However, Major challenges face by market player such as development of new antibacterial drugs, and the low cost of development of novel antibacterial formulations which makes it difficult for pharma industries to recover their investments.
New Product launch to flourish the market:
Major Key market manufacturer have been focusing on increasing research and development activities and producing new product solution for specific applications as there are varying demands based on the utilization. Leading pseudomonas aeruginosa treatment market players have determined how improved accuracy can be influential in many applications. In 2019, “Merck & Co. Inc.”, has received U.S.FDA approval for “Zerbaxa”. This product used to treat adult patients with nosocomial pneumonia, and ventilator-related pneumonia, caused by certain susceptible gram-negative microorganisms. In 2019, “Allergan Inc.”, has received U.S. FDA approval for the “AVYCAZ treatment”. This product used to treat intra-abdominal infections (cIAI) and urinary tract infections (cUTI) in pediatric patients. In 2019, “Teva pharmaceutical” has launched new solution such as “Tobramycin inhalation solution”. This medicine used to treat people with cystic fibrosis who have a bacterial infection known as Pseudomonas aeruginosa. In 2019, “Pfizer” has recivedd U.S.FDA approval for “Zavicefta” (ceftazidime-avibactam) drug product. It contains of a combination of avibactam and ceftazidime. It is a fixed-dose combination antibacterial developed to treat serious Gram-negative bacterial infections.
Key benefits of the report:
- This study presents the analytical depiction of the global pseudomonas aeruginosa treatment market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global pseudomonas aeruginosa treatment market share.
- The current market is quantitatively analyzed to highlight the global pseudomonas aeruginosa treatment market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global pseudomonas aeruginosa treatment market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the Pseudomonas Aeruginosa Treatment Market research report:
- Who are the leading market players active in pseudomonas aeruginosa treatment market?
- What are the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that will help in taking further strategic steps?
Pseudomonas Aeruginosa Treatment Market Report Highlights
By Drug Type
By Route of Administration
By Distribution Channel
Key Market Players
Bristol-Myers Squibb Co, Teva Pharmaceutical Industries Ltd., AstraZeneca, Janssen Pharmaceuticals, Inc., CARB-X Company, Allergan plc, Lupin Pharmaceuticals, Inc, Pfizer, Inc.., Merck and Co., Inc., Novartis Ag